A Case Report of a Long-Surviving Elderly Patient with Lung Squamous Cell Carcinoma and Oncogenic Driver Alterations

Abstract

Abstract Background: MET (mesenchymal-epithelial transition) and Epidermal growth factor receptor (EGFR) mutations have a low incidence in lung squamous cell carcinoma (LUSC). For patients with MET/EGFR TKI (Tyrosine Kinase Inhibitor)-resistant driver gene mutation-related non-small cell lung cancer, selection of an appropriate treatment strategy is more difficult. Case presentation: This paper describes a patient who was diagnosed with local advanced LUSC (stage cT2N3M0), harboring MET and EGFR mutations. This patient received toripalimab in combination with chemotherapy and achieved a partial response, with long-term progression-free survival of more than 36 months. During the treatment, no adverse events occurred. Conclusions: Immune checkpoint inhibitors may be considered as a later-line treatment option for patients with MET-mutated advanced LUSC.